Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

Stopped The decision to end the study was based on a change in GSK strategy. No subjects were enrolled into the study.

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

• DRUG: Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists
• DRUG: Fluticasone furoate/umeclidinium/vilanterol

Sponsor

GlaxoSmithKline